Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands

Multiple Sclerosis

Volumn 16, Issue 7, 2010, Pages 810-815

  Bosca, I ^a   Villar, L M ^b   Coret, F ^c   Magraner, M J ^a   Simo Castello M ^a   Alvarez Cermeno J C ^b   Casanova, B ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c Neurology Service Hospital Clínic de Valencia   (Spain)

Author keywords

beta interferon; cerebrospinal fluid; multiple sclerosis; oligoclonal bands; outcome measurement

Indexed keywords

BETA1A INTERFERON; IMMUNOGLOBULIN M; INTERFERON BETA SERINE; OLIGOCLONAL BAND; BETA INTERFERON; IMMUNOLOGIC FACTOR; LIPID; NEUTRALIZING ANTIBODY;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENCE RISK; TREATMENT RESPONSE; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DISABILITY; IMMUNOLOGY; KAPLAN MEIER METHOD; MULTICENTER STUDY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SPAIN; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES, NEUTRALIZING; CHI-SQUARE DISTRIBUTION; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; INTERFERON-BETA; KAPLAN-MEIER ESTIMATE; LIPIDS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OLIGOCLONAL BANDS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPAIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955033531     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510371961     Document Type: Article

References (20)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993 ; 43: 655-661.
2. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing Multiple sclerosis. Ann Neurol 1996 ; 39: 285-294.
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998 ; 352: 1498-1504.
4. Cohen BA, Khan O., Jeffery DR, Bashir K., Rizvi SA, Fox EJ, et al. Identifying and treating patients with suboptimal responses. Neurology 2004 ; 63: S33 - S40.
5. Liu C. and Blumhardt LD Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better? Mult Scler 1999 ; 5: 22-28.
6. OgRourke K., Walsh C., Antonelli G. and Hutchinson M. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007 ; 13: 336-342.
7. Bosca I., Coret F., Valero C., Pascual AM, Magraner MJ, Landete L., et al. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta interferon. Mult Scler 2008 ; 14: 636-639.
8. Villar LM, Masjuan J., Gonzólez-Porquó P., Plaza J., Sódaba MC, Roldón E., et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002 ; 59: 556-559.
9. Villar LM, Masjuan J., Gonzólez-Porquó P., Plaza J., Sódaba MC, Roldón E., et al. Intrathecal IgM synthesis is a prognostic factor in multiple Sclerosis. Ann Neurol 2003 ; 53: 222-226.
10. Villar LM, Masjuan J., Gonzólez-Porquó P., Plaza J., Sódaba MC, Roldón E., et al. Intrathecal IgM synthesis in neurological diseases. Relationship with disability in MS. Neurology 2002 ; 58: 824-826.
11. Villar LM, Sódaba MC, Roldón E., Masjuan J., Gonzólez-Porquó P., Villarrubia N., et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005 ; 115: 187-194.
12. Thangarajh M., Gomez-Rial J., Hedstróm AK, Hillert J., Alvarez-Cermeóo JC, Masterman T., et al. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler 2008 ; 14: 1208-1213.
13. Garcóa-Barragón N., Villar LM, Espióo M., Sódaba MC, Gonzólez-Porquó P. and Alvarez-Cermeóo JC Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment. Eur J Neurol 2009 ; 16: 380-385.
14. Polman CH, Reingold SC, Edan G., Filippi M., Hartung HP, Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteriag. Ann Neurol 2005 ; 58: 840-846.
15. Poser CM, Paty DW, Scheinberg L., McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 ; 13: 227-231.
16. Villar LM, Gonzólez-Porquó P., Masjuón J., Alvarez-Cermeóo JC, Bootello A. and Keir G. A sensitive and reproducible method for the detection of oligoclonal IgM bands. J Immunol Methods 2001 ; 258: 151-155.
17. Sódaba MC, Gonzólez-Porquó P., Masjuan J., ólvarezCermeóo JC, Bootello A. and Villar LM An ultrasensitive method for the detection of oligoclonal IgG bands. J Immunol Methods 2004 ; 284: 141-145.
18. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 ; 343: 898-904.
19. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernóndez O., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001 ; 357: 1576-1582.
20. Kappos L., Polman CH, Freedman MS, Edan G., Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006 ; 67: 1242-1249.